NCT01242202View on ClinicalTrials.gov

A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

October 21, 2010

Primary Completion Date

May 25, 2012

Study Completion Date

May 25, 2012

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

ipragliflozin

oral

DRUG

alpha glucosidase inhibitor

oral

Trial Locations (6)

Unknown

Chūbu

Hokkaido

Kansai

Kantou

Kyushu

Tōhoku

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT01242202 - A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients | Biotech Hunter | Biotech Hunter